Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Photorefractive keratectomy with Mitomycin C and extended wear contact lens for high risk cases of previous LASIK, PK, DALK and RK

Poster Details

First Author: H.Khakshour IRAN

Co Author(s):    L. Saffarian   A. Vejdani   H. Ghooshkhanei              

Abstract Details

Purpose:

To evaluate the refractive results of photorefractive keratectomy (PRK) with adjunctive mitomycin C (MMC) and extended wear contact lens after previous refractive surgeries.

Setting:

Navid didegan Eye clinic, Iran

Methods:

This retrospective case series consisted of 45 eyes of 27 patients who had primary procedures including LASIK, PK, DALK and RK. MMC and bandage contact lens was used after PRK to prevent corneal haze. Visual acuity, refraction and keratometry were analyzed preoperatively and months after operation. Mean follow up time was months (range: 2 to 12 months).

Results:

There were a total of 45 PRK procedures performed on 27 eyes with previous LASIK, 5 eyes with DALK, 4 PK, 9 eyes who had primary RK. The mean spherical equivalent (SE) in LASIK group was -1.82 preoperatively changed to -0.47 (p=0.018). Changes in UCVA and Cylinder for previous DALK were 0.32 to 0.58(p=0.04) and -4.93± 2.6 to -2.37 ± 1.2(p=0.05), respectively. Previous PK group SE changed from -7.04± 2.34 to -0.70 ± 0.75(p=0.036) and RK patient group UCVA improved from 0.23 to 0.57 (p=0.013) and also Cylinder decreased from -2.54 ±1.01 to -0.87 ± 0.88 (p=0.012).

Conclusions:

PRK with MMC and contact lens is effective method for treatment of refractive errors occurring after other corrective procedures. Further studies with more patients in each group will clarify more details.

Financial Disclosure:

NONE

Back to Poster listing